Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men
The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Abstract
Context: The impact of serum androgen manipulation on prostate tissue hormone levels in normal men is unknown. Studies of men with prostate cancer have suggested that prostatic androgens are preserved in the setting of castration. Tissue androgens might stimulate prostate growth, producing adverse clinical consequences. Objective: The objective of the study was to determine the effect of serum androgen manipulation on intraprostatic androgens in normal men. Design: Thirteen male volunteers ages 35–55 yr (prostate-specific antigen < 2.0 ng/ml; normal transrectal ultrasound) were randomly assigned to: 1) a long-acting GnRH-antagonist, acyline, every 2 wk; 2) acyline plus testosterone (T) gel (10 mg/d); or 3) placebo for 28 d. Serum hormones were assessed weekly. Prostate biopsies were obtained on d 28. Extracted androgens were measured by RIA, and immunohistochemistry for androgen-regulated proteins was performed. Results: The mean decrease in serum T was 94%, whereas prostatic T and dihydrotestosterone levels were 70 and 80% lower, respectively, in subjects receiving acyline alone compared with controls (P < 0.05). Despite this decrease in prostate androgens, there were no detectable differences in prostate epithelial proliferation, apoptosis, prostate-specific antigen, and androgen receptor expression. Conclusion: In this small study of healthy subjects, despite a 94% decrease in serum T with medical castration, intraprostatic T and dihydrotestosterone levels remained 20–30% of control values, and prostate cell proliferation, apoptosis, and androgen-regulated protein expression were unaffected. Our data highlight the importance of assessing tissue hormone levels. The source of persistent prostate androgens associated with medical castration and their potential role in supporting prostate metabolism deserves further study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [38]
Citations
Cites
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082 · cited 2×
“known to be androgen-regulated (28, 29)] between the medically castrate group and the control subjects (Table 3).”
BackgroundSuicidal Tendencies: Apoptotic Cell Death by Caspase Family Proteinases
Wolf, B. B., & Green, D. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20049 · Cited by 942
Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., & Andriole, G. (2002) · Urology · doi:10.1016/s0090-4295(02)01905-2 · Cited by 729
Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.
Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., & Russell, D. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116665 · Cited by 727 · cited 1×
“The prostate expresses high levels of type II 5 -reductase (1, 2) and enzymes involved in steroid metabolism (3, 4); therefore the endocrine milieu within the prostate may substantially differ from that of serum.”
BackgroundThe Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675 · cited 3×
“(15) who found a preservation of prostate T concentrations in hormone-refractory prostate cancer despite a minimum of 6 months of medical or surgical castration.”
BackgroundResultWolf, B. B., Schuler, M., Echeverri, F., & Green, D. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30651 · Cited by 487
Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., & Hobbs, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030330 · Cited by 467
Metabolism of anabolic androgenic steroids
Schänzer, W. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.7.1001 · Cited by 372 · cited 1×
“Although the half-life of serum T is in the order of hours (35), the half-life of tissue androgens is not known, and it is possible that longer periods of androgen ablation are required to see changes in prostate epithelial cell proliferation or apoptosis.”
BackgroundLabrie, F., Luu-The, V., Labrie, C., & Simard, J. (2001) · Frontiers in Neuroendocrinology · doi:10.1006/frne.2001.0216 · Cited by 366 · cited 2×
“Although it is possible that intraprostatic androgens arise from residual testicularderived serum androgens, the prostate has been shown to express, at least at the transcript level, all the enzymatic machinery required to convert adrenal precursors such as androstenedione, DHEA, and DHEA-S to DHT (3, 4), and increase…”
BackgroundPeters, C. A., & Walsh, P. C. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709033171004 · Cited by 337 · cited 1×
“Very small but detectable changes in total and transitional zone volume have been observed with treatment using a potent 5 -reductase inhibitor as soon as 1 month in a very large cohort (36), although a previous small study of a GnRH agonist failed to detect changes in prostate size at 1 month (37).”
Background
Cited by
Items 201–232 of 232
The effect of cissampelos capensis extract on prostate cancer, sertoli and leydig cell function
Pearce, K. M. (2014) · University of the Western Cape Electronic Theses and Dissertations Repository (University of the Western Cape) · Cited by 1
The Role of Insulin-Like Growth Factor Signaling in Prostate Cancer Development and Progression
Montgomery, B., Dean, J. P., & Plymate, S. R. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0598-6_5
Vía trasera de la síntesis de testosterona (backdoor pathway)
Arcila, J. F. U. (2016) · Revista Urología Colombiana / Colombian Urology Journal · doi:10.1016/j.uroco.2015.11.002
Hormone-Based Therapies for Castration-Resistant Prostate Cancer
Mostaghel, E. A., & Nelson, P. S. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_74
Self-citationReview Article Role of Testosterone in Managing Advanced Prostate Cancer
Rove, K. O., Debruyne, F. M. J., Djavan, B., Gomella, L. G., Koul, H. K., Lucia, M. S., Petrylak, D. P., Shore, N. D., Stone, N. N., & Crawford, E. D. (2012)
Hormonotherapy of Bone Metastases
Kamposioras, K. V., & Briasoulis, E. C. (2009) · Cancer metastasis · doi:10.1007/978-1-4020-9819-2_15
“ulate to hyperactive status in hormone-refractory phenotype [151–156].”
BackgroundMeme ve prostat kanserinde Pirna’lar ile hormonal regülasyonun ilişkisi
Öner, Ç. (2015) · ESOGU Academic Open Access System (Eskişehir Osmangazi University)
Is There A Role for Dihydrotestosterone/ Estradiol Ratio in Premature Ejaculation?
Eldaraky, M. E. A., El-Kamel, M. F., & Marzouk, H. F. A. (2021) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2021.160883
Androgen Receptors in the Pathology of Disease
Leung, J. K., Tien, A. H., & Sadar, M. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-78315-0_16 · Cited by 1
Uso de hormonas en fertilización
Parez, V. (1993) · Boletín de Cunicultura
Prostate Cancer Steroid Hormones
Montgomery, B. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_6811 · Cited by 1
de Jong, F. H. (2009) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1111140.621020
Faculty Opinions recommendation of Abiraterone and increased survival in metastatic prostate cancer.
Poppel, H. V., & Tolkach, Y. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.11812958.15779296
Bell, D. S. H., & Jerkins, T. W. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01256-6
“However, castration only lowers the levels of DHT by 20% to 30% while testosterone levels are lowered by 94% [18].”
BackgroundNelson, P. S. (2012) · Urology · doi:10.1016/j.urology.2012.01.093
Self-citationAnalyse d’articles — avec la collaboration de la Société Francophone de Médecine Sexuelle (SFMS)
Buvat, J. (2011) · Basic and Clinical Andrology · doi:10.1007/s12610-011-0153-4
Montgomery, B., Mostaghel, E. A., Vessella, R. L., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2023) · doi:10.1158/0008-5472.c.6497580
Self-citationWright, J. L., Kwon, E. M., Ostrander, E. A., Montgomery, B., Lin, D. W., Vessella, R. L., Stanford, J. L., & Mostaghel, E. A. (2023) · doi:10.1158/1055-9965.c.6515046
Self-citationShi, L., Yan, Y., He, Y., Yan, B., Pan, Y., Orme, J. J., Zhang, J., Xu, W., Pang, J., & Huang, H. (2023) · doi:10.1158/0008-5472.c.6513072.v1
Intraprostatic hormone dosage: Validation of a novel prostate biopsy technique
Pattou, M., Neuzillet, Y., Raynaud, J., Radulescu, C., Fiet, J., Giton, F., Labro, M., Lebrét, T., & Botto, H. (2024) · The French Journal of Urology · doi:10.1016/j.fjurol.2024.102659
Androgens and benign prostatic hyperplasia
Nicholson, T. M., Farrant, M. T., & Page, S. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00105-9
Self-citationAndrogenrezeptor in Gesundheit und Krankheit
Hohl, A., & Marcelli, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_2
Androgen and Androgen Receptor-Directed Therapy as Initial Treatment for Prostate Cancer
Montgomery, B., & Nelson, P. S. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_73
Self-citationAndrogen receptor therapy resistance in prostate cancer: From the disease model to the mechanisms
Huhtaniemi, R. (2024) · UTUPub (University of Turku) · Cited by 1
Liu, Y., Qian, D., Ding, Y., Wu, D., Tang, C., Xu, C., & Chen, X. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149810
Bousset, L. (2019) · theses.fr (ABES) · doi:10.70675/45b0b676z18daz47a9zbb03zee607f300175 · Cited by 2
Adrenal-derived factors drive progression of sclerotic prostate cancer in bone
Thulin, M. H., Li, L., Abrahamsson, S., Landin, A., Horkeby, K., Wu, J., Lagerquist, M. K., Ohlsson, C., & POUTANEN, M. H. (2026) · Endocrine Related Cancer · doi:10.1530/erc-25-0309
“ADT lowers circulating testosterone levels by more than 90% by suppressing testicular production, and the remaining 5 – 10% of testosterone is believed to originate from peripheral conversion of adrenal-derived precursors (8, 9, 10, 11).”
Die Wirkung von Valproat auf die Konochenmetastasenzellen (VCaP) des Prostatakarzinoms
Früchtenicht, T. (2011) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1070
Molecular Biology of Novel Targets Identified Through Study of Castration-Recurrent Prostate Cancer
Watson, P. A., & Sawyers, C. L. (2009) · Springer eBooks · doi:10.1007/978-0-387-69179-4_32
Macfarlane, R. J., Hovens, C. M., Corcoran, N. M., & Chi, K. N. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_76
Metadata
- Authors
- Page, S. T., Lin, D. W., Mostaghel, E. A., Hess, D. L., True, L. D., Amory, J. K., Nelson, P. S., Matsumoto, A. M., & Bremner, W. J.
- Affiliations
- VA Puget Sound Health Care System (US)
- Departments of Medicine (S.T.P., E.A.M., J.K.A., P.S.N., A.M.M., W.J.B.), Seattle, Washington 98195
- Oregon National Primate Research Center (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Corresponding author
- Page, Stephanie T.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-10-01
- Volume
- 91
- Issue
- 10
- Pages
- 3850-3856
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2155279970
- Cited by
- 229
- References
- 43
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 9 · 2022: 6 · 2021: 7 · 2020: 6 · 2019: 8 · 2018: 5 · 2017: 10 · 2016: 8 · 2015: 11 · 2014: 19 · 2013: 21 · 2012: 19
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5u54hd012629-31)
- National Institute on Aging (K23AG027238)
- National Cancer Institute (CA 97186, P50CA097186)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK065204, DK65204, DK 65083, K23DK065083)
- National Center for Research Resources (RR-00163.)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD042454, U54-HD-12629)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- medical castration, GnRH antagonist, acyline, testosterone gel, dihydrotestosterone, prostate-specific antigen, androgen receptor, apoptosis, healthy men
- MeSH terms
- Adult, Androgens, Follicle Stimulating Hormone, Humans, Immunohistochemistry, Luteinizing Hormone, Male, Middle Aged, Orchiectomy, Prostate, Dihydrotestosterone, Testosterone, Prostate-Specific Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.